ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1PFE | PFIZER INC | Healthcare | $164.33B | 12.18% |
2MDT | MEDTRONIC PLC | Healthcare | $129.18B | 9.58% |
3BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 9.45% |
4CVS | CVS HEALTH CORP | Healthcare | $114.88B | 8.52% |
5HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 7.75% |
6ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 6.89% |
7CI | CIGNA GROUP | Healthcare | $78.07B | 5.79% |
8BSX | BOSTON SCIENTIFIC CORP | Healthcare | $64.07B | 4.75% |
9GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 2.74% |
10CNC | CENTENE CORP | Healthcare | $34.79B | 2.58% |
11ZTS | ZOETIS INC | Healthcare | $33.71B | 2.50% |
12LH | LABCORP HOLDINGS INC | Healthcare | $30.23B | 2.24% |
13DGX | QUEST DIAGNOSTICS INC | Healthcare | $28.57B | 2.12% |
14VTRS | VIATRIS INC | Healthcare | $23.70B | 1.76% |
15THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 1.69% |
16ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 1.56% |
17ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 1.47% |
18JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 1.14% |
19EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 1.02% |
20COO | COOPER COMPANIES INC | Healthcare | $11.83B | 0.88% |
21ALGN | ALIGN TECHNOLOGY INC | Healthcare | $11.77B | 0.87% |
22UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.83% |
23DVA | DAVITA INC | Healthcare | $10.95B | 0.81% |
24BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 0.74% |
25OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.74% |
26GMED | GLOBUS MEDICAL INC | Healthcare | $9.58B | 0.71% |
27HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.71% |
28ATR | APTARGROUP INC | Healthcare | $8.98B | 0.67% |
29TFX | TELEFLEX INC | Healthcare | $6.07B | 0.45% |
30EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.37% |
31OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.35% |
32SHC | SOTERA HEALTH CO | Healthcare | $4.66B | 0.35% |
33ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 0.33% |
34NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.29% |
35OGN | ORGANON & CO | Healthcare | $3.65B | 0.27% |
36ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.23% |
37BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.23% |
38ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.22% |
39AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.20% |
40ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.18% |
41MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.18% |
42AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.16% |
43PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.16% |
44BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.16% |
45VCYT | VERACYTE INC | Healthcare | $1.99B | 0.15% |
46HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.15% |
47XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.14% |
48ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.13% |
49INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.13% |
50NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.13% |
51HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.13% |
52ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.12% |
53OMCL | OMNICELL INC | Healthcare | $1.61B | 0.12% |
54TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.12% |
55CNMD | CONMED CORP | Healthcare | $1.50B | 0.11% |
56PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.11% |
57AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.11% |
58PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.11% |
59ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.11% |
60INVA | INNOVIVA INC | Healthcare | $1.35B | 0.10% |
61OMER | OMEROS CORP | Healthcare | $1.30B | 0.10% |
62AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.09% |
63VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.09% |
64NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.09% |
65IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.08% |
66AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.08% |
67BVS | BIOVENTUS INC | Healthcare | $915M | 0.07% |
68HSTM | HEALTHSTREAM INC | Healthcare | $867M | 0.06% |
69RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.06% |
70MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.06% |
71PHR | PHREESIA INC | Healthcare | $783M | 0.06% |
72VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.06% |
73QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.05% |
74ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.05% |
75CTEV | CLARITEV CORP | Healthcare | $459M | 0.03% |
76PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.03% |
77EMBC | EMBECTA CORP | Healthcare | $364M | 0.03% |
78VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.03% |
79AGEN | AGENUS INC | Healthcare | $311M | 0.02% |
80INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.02% |
81QTTB | Q32 BIO INC | Healthcare | $264M | 0.02% |
82SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.02% |
83PDEX | PRO DEX INC | Healthcare | $216M | 0.02% |
84ELMD | ELECTROMED INC | Healthcare | $204M | 0.02% |
85PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
86RLYB | RALLYBIO CORP | Healthcare | $84M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $1.35T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 33% toward Growth. +3% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T052248 rates=20261113T052248
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 30.8% | -44.9% |
| 3 yearsp.a. | 16.0% | -25.6% |
| 5 yearsp.a. | 9.3% | -12.8% |
| 10 yearsp.a. | 11.7% | -6.1% |
| Since inceptionp.a. | 12.9% | -5.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 32.5% | -41.2% |
| 2025 | 19.8% | -17.7% |
| 2024 | -6.2% | 6.1% |
| 2023 | -4.3% | -24.4% |
| 2022 | 0.9% | 23.3% |
| 2021 | 24.6% | 35.1% |
| 2020 | 12.2% | -17.7% |
| 2019 | 19.2% | -3.9% |
| 2018 | 5.6% | 16.2% |
| 2017 | 19.7% | -14.0% |
| 2016 | -5.6% | 9.6% |
| 2015 | 7.4% | -5.5% |
| 2014 | 25.6% | -14.2% |
| 2013 | 35.8% | -15.6% |
| 2012 | 18.1% | -20.6% |
| 2011 | 14.3% | 39.4% |
| 2010 | 13.1% | -1.7% |
| 2009 | 33.7% | 8.5% |
| 2008 | -21.3% | 8.9% |
| 2007 | 3.5% | 28.2% |
| 2006 | 19.8% | 17.5% |
| 2005 | 5.0% | 10.4% |
| 2004 | 19.8% | 17.5% |
| 2003 | 38.1% | -29.0% |
| 2002 | -17.1% | 50.9% |
| 2001 | 8.5% | -13.9% |
| 2000 | 71.3% | -66.2% |
| 1999 | 5.6% | -26.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Cash-Flow Yield Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Cash-Flow Yield signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.